Acalabrutinib vs. Ibrutinib | Doctor Biases Against Patients | Nivolumab + Relatlimab SuccessJune 09, 2021 | Oncology Hematology First Results of a Head-to-Head Trial of Acalabrutinib vs. Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia It’s a battle of two heavyweights in this trial report from the Journal of Clinical Oncology, sharing the results of acalabrutinib (Calquence) compared to ibrutinib (Imbruvica) in treating chronic lymphocytic leukemia (CLL). Selected events of clinical interest included cardiac events, atrial fibrillation, ventricular tachyarrhythmias, hypertension, bleeding and major bleeding events, infections, and second primary malignancies excluding non-melanoma skin cancers. Read full article Allergy & Immunology Avoid These 7 Common Doctor Biases About Patients Are you biased toward certain types of patients? “Sometimes” is likely your answer, but there are implicit biases that doctors may not be aware they have. To help answer this question, Medscape put together a survey to weigh these biases, with emotional problems coming in at No. 1. Whether they are implicit or explicit, here are the other patient characteristics that commonly trigger a predisposition in doctors. Read full article Dermatology Immunotherapy Combination Shows Benefit for Patients w. Advanced Melanoma, Phase 3 Trial Shows The results of the trial, known as the RELATIVITY-047 study, were presented at the virtual ASCO Annual Meeting that took place June 4-8, 2021. The Dana-Farber Cancer Institute Investigators who co-led the study were thrilled to present that, despite PD-1 blocker nivolumab revolutionizing the treatment of patients with advanced melanoma, this fixed-dose combination of nivolumab and LAG-3 target relatlimab holds the cancer in check significantly longer than nivolumab alone. Read full article
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS